Lineage Cell Therapeutics Inc.
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
LCTX | TA
Overview
Corporate Details
- ISIN(s):
- US53566P1093
- LEI:
- Country:
- Israel
- Address:
- Derech Menachem Begin 121, 6701203 Tel Aviv
- Website:
- https://lineagecell.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel allogeneic ("off-the-shelf") cell therapies for serious neurological and ophthalmic conditions. The company's proprietary platform utilizes directed differentiation processes on pluripotent cell lines to manufacture specialized human cells. These cells are designed to be transplanted into patients to replace or support cells that are absent or dysfunctional due to degenerative disease, aging, or traumatic injury, with the goal of restoring functional activity. Lineage leverages its technology and manufacturing capabilities to advance its programs internally and through strategic partnerships.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-09 07:46 |
Earnings Release
Immediate Report
|
English | 102.5 KB | ||
| 2025-11-09 07:46 |
Foreign Filer Report
Immediate Report
|
English | 36.6 KB | ||
| 2025-09-08 20:22 |
Regulatory News Service
Immediate Report
|
English | 30.9 KB | ||
| 2025-09-08 20:22 |
Foreign Filer Report
Immediate Report
|
English | 36.5 KB | ||
| 2025-08-13 11:32 |
Earnings Release
Second Quarter 2025 Financial Results and Provides Business Update
|
English | 69.6 KB | ||
| 2025-08-13 11:32 |
Foreign Filer Report
Second Quarter 2025 Financial Results and Provides Business Update
|
English | 36.5 KB | ||
| 2025-07-03 15:05 |
Director's Dealing
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula
|
Hebrew (modern) | 117.3 KB | ||
| 2025-07-03 15:05 |
Foreign Filer Report
FORM 4- STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Jayasuriya Anula
|
English | 36.6 KB | ||
| 2025-07-03 15:00 |
Director's Dealing
FORM4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.
|
Hebrew (modern) | 117.7 KB | ||
| 2025-07-03 15:00 |
Major Shareholding Notification
FORM4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Mulroy Michael H.
|
English | 36.5 KB | ||
| 2025-07-03 14:55 |
Post-Annual General Meeting Information
FORM 8-K-The Annual Meeting - final voting results
|
Hebrew (modern) | 128.3 KB | ||
| 2025-07-03 14:55 |
Declaration of Voting Results & Voting Rights Announcements
FORM 8-K-The Annual Meeting - final voting results
|
English | 36.5 KB | ||
| 2025-06-23 20:53 |
Proxy Solicitation & Information Statement
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
|
English | 2.8 MB | ||
| 2025-06-23 20:53 |
Foreign Filer Report
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held June 26, 2025
|
English | 36.5 KB | ||
| 2025-05-14 12:01 |
Earnings Release
First Quarter 2025 Financial Results and Provides Business Update
|
English | 64.9 KB |
Automate Your Workflow. Get a real-time feed of all Lineage Cell Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lineage Cell Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lineage Cell Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
